J&J To Promote Dapoxetine With “Responsible” DTC Campaign
Executive Summary
Johnson & Johnson plans to support the launch of the premature ejaculation therapy dapoxetine with a "responsible" direct-to-consumer advertising campaign, J&J Consumer Pharmaceuticals & Nutritionals Group Chairman Rosemary Crane said May 26 during the company's R&D day in New York
You may also be interested in...
FDA Adult Antidepressant Suicidality Analysis Will Take At Least A Year
FDA expects its assessment of data on suicidal thinking and behavior in adults on antidepressants will take at least a year to complete
FDA Adult Antidepressant Suicidality Analysis Will Take At Least A Year
FDA expects its assessment of data on suicidal thinking and behavior in adults on antidepressants will take at least a year to complete
DTC Restrictions Ahead: Risk Management Plans, “Drug Watch” Are Vehicles
FDA will manifest its tougher stance on DTC advertising in requirements for more extensive risk management plans, Hogan & Hartson Partner Robert Brady predicted at a Regulatory Affairs Professionals Society conference in Chicago